Shionogi gains Asian rights to SAGE-217

Shionogi & Co. Ltd. (Tokyo:4507) licensed exclusive rights to SAGE-217 from Sage Therapeutics Inc. (NASDAQ:SAGE) in Japan, Taiwan and South

Read the full 208 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE